

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): April 28, 2022**

**INMED PHARMACEUTICALS INC.  
(Exact Name of Company as Specified in Charter)**

**British Columbia**  
(State or Other Jurisdiction  
of Incorporation)

**001-39685**  
(Commission File Number)

**98-1428279**  
(IRS Employer  
Identification No.)

**InMed Pharmaceuticals Inc.  
Suite 310 - 815 W. Hastings Street,  
Vancouver, B.C.  
Canada**  
(Address of Principal Executive Offices)

**V6C 1B4**  
(Zip Code)

**Company's telephone number, including area code: (604) 669-7207**

**Not applicable  
(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<b>Title of each class</b>	<b>Trading Symbol(s)</b>	<b>Name of each exchange on which registered</b>
<b>Common Shares, no par value</b>	<b>INM</b>	<b>The Nasdaq Stock Market LLC</b>

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 7.01 Regulation FD Disclosure.**

On April 28, 2022, the Company announced the publication of a patent application in North America for several cannabinoid analogs. This patent application has broad claims directed to their molecular structure, uses and methods of manufacturing.

The information set forth in this Item 7.01, including Exhibits 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits:

The following exhibits shall be deemed to be furnished, and not filed:

<b>Exhibit No.</b>	<b>Description</b>
99.1	<a href="#">News release, dated April 28, 2022</a>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INMED PHARMACEUTICALS INC.

Date: April 28, 2022

By: /s/ Brenda Edwards  
Brenda Edwards  
Interim, Chief Financial Officer



NASDAQ: INM

Suite 310-815 W. Hastings St.  
Vancouver, BC, Canada V6C 1B4  
Tel: +1.604.669.7207  
Email: [info@inmedpharma.com](mailto:info@inmedpharma.com)  
[www.inmedpharma.com](http://www.inmedpharma.com)

**InMed Expands Patent Portfolio with Novel Cannabinoid Analogs and  
Advances Collaboration Agreement with Leading Cannabinoid Research Expert**

- *Expands library of proprietary cannabinoid analogs for pharma R&D*
- *Research collaboration initiated to screen analogs for therapeutic uses*

Vancouver, BC and South San Francisco, CA – April 28, 2022 – **InMed Pharmaceuticals Inc.** (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is pleased to announce the publication of a patent application in North America for several cannabinoid analogs. This patent application has broad claims directed to their molecular structure, uses and methods of manufacturing.

Entitled “Cannabinoid Analogs and Methods for their Preparation”, the patent application describes several new cannabinoid-related chemical compounds that have not been previously described. If granted, the broad patent application allows for the creation of several variations of novel cannabinoid compounds, producing a robust library of proprietary new chemical entities (‘NCEs’).

Scientists at BayMedica, LLC, InMed’s subsidiary in the US, designed and produced these cannabinoid analogs. These NCEs are expected to offer similar or improved therapeutic effects compared to their parent (naturally occurring) cannabinoid with modifications that may make them preferred candidates to treat specific diseases.

Eric Hsu, SVP, Pre-Clinical Research and Development for InMed commented; “We believe rare cannabinoids hold tremendous therapeutic potential that may address a number of unmet medical needs. This patent covers the selective modification of naturally occurring cannabinoids to target specific properties for pharmaceutical development. Such patent protection is an important component to ensure long-term commercial exclusivity as we continue to invest in R&D.”

InMed has initiated a research collaboration with the Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila (Italy) in the laboratory of Dr. Mauro Maccarrone, an international expert in cannabinoid research and founding member of the European Cannabinoid Research Alliance. He is also the 2007 recipient of the International Association for Cannabinoid Medicines’s prestigious Ester Friderici Award for Basic Research, and the 2016 recipient of the International Cannabinoid Research Society’s prestigious Mechoulam Award. Dr. Maccarrone’s lab will be screening the Company’s novel cannabinoid analogs to investigate pharmacological properties and potential therapeutic uses.

**Creating a robust patent library of NCEs**

The patent application covers technology that allows for the creation of libraries of NCEs that can be compared to other drugs in order to select candidates for advancement. The cannabinoid analogs were manufactured in a biosynthetic process using the yeast *S. cerevisiae*, which is commonly used to produce therapeutic biologicals and vaccines.

Filing this patent application in a number of global jurisdictions further emphasizes the Company’s commitment towards developing NCEs and enhancing rare cannabinoids R&D opportunities.

---

## Why pursue cannabinoid analogs?

Unlike natural cannabinoids isolated from the plant which are not patentable, these cannabinoid analogs are patentable. Benefits may include:

- Targeting certain physiological outcomes in specific diseases;
- Improving upon the safety profile of the natural cannabinoids;
- Enhancing the ability to integrate with specific delivery technologies; and
- Protecting the long-term research investment and commercial opportunities.

Learn more about InMed's Cannabinoid Analogs:

Novel Patentable Cannabinoid Analogs | InMed Pharmaceuticals

Learn more about InMed's Cannabinoids in Development: <https://www.inmedpharma.com/pharmaceutical/cannabinoids-in-development/>

**About InMed:** InMed Pharmaceuticals is a global leader in the research, development, manufacturing and commercialization of rare cannabinoids. Together with its subsidiary BayMedica, LLC, the Company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is also a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit [www.inmedpharma.com](http://www.inmedpharma.com) and [www.baymedica.com](http://www.baymedica.com).

### Investor Contact:

Colin Clancy  
Senior Director, Investor Relations  
T: +1.604.416.0999  
E: [cclancy@inmedpharma.com](mailto:cclancy@inmedpharma.com)

### Cautionary Note Regarding Forward-Looking Information:

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: expanding patent portfolio with novel cannabinoid analogs; advancing collaboration agreement with leading cannabinoid research expert; screening analogs for therapeutic uses; publication of patent application in North America for several cannabinoids analogs; the patent has broad claims directed to molecular structure, uses and methods of manufacturing; NCEs are expected to offer similar or improved therapeutic effects compared to their parent (naturally occurring) cannabinoid with modifications that may make them preferred candidates to treat specific diseases; cannabinoids hold tremendous therapeutic potential that may address a number of unmet medical needs; patent application covering technology that allows for the creation of libraries of NCEs that can be compared to other drugs in order to select candidates for advancement; screening the Company's novel cannabinoid analogs to investigate pharmacological properties and potential therapeutic uses; benefits of analogs that may include targeting certain physiological outcomes in specific diseases, improving upon the safety profile of the natural cannabinoids; enhancing the ability to integrate with specific delivery technologies; protecting the long-term research investment and commercial opportunities; being a global leader in the research, development, manufacturing and development of rare cannabinoids; and delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs.

With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.

Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-K and other filings with the Security and Exchange Commission on [www.sec.gov](http://www.sec.gov).

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

---